Elevation Oncology, Inc. reported earnings results for the fourth quarter ended December 31, 2023. For the fourth quarter, the company reported net loss was USD 7.9 million compared to USD 19.04 million a year ago. Basic loss per share from continuing operations was USD 0.19 compared to USD 0.82 a year ago.
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
3.62 USD | -0.69% | -4.74% | +574.12% |
Apr. 05 | Elevation Oncology, Inc. Announces Management Changes | CI |
Mar. 27 | Merrimack Gets $225 Million Milestone Payment, Schedules Meeting For Dissolution Plan | MT |
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+574.12% | 198M | |
-2.31% | 103B | |
+0.56% | 95.28B | |
+0.79% | 22.15B | |
-17.37% | 21.02B | |
-9.03% | 18.15B | |
-41.01% | 16.73B | |
-14.85% | 16.05B | |
+3.21% | 13.68B | |
+33.54% | 12.17B |
- Stock Market
- Equities
- ELEV Stock
- News Elevation Oncology, Inc.
- Elevation Oncology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023